GlassScriptPhysician profile
Clelia B Lima
NPI 1538310164
$3,396.75
in general payments reported to CMS, 2019-2025
20 companies · $859 in 2025
The $859 reported for 2025 was more than what 84% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $191 · 2022: $746 · 2023: $651 · 2024: $950 · 2025: $859.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,359 · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $100.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,359.30 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $100.17 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Gilead Sciences, INC. | $374.30 | 2022-2025 | Livdelzi, Epclusa |
| Neurocrine Biosciences, INC. | $358.82 | 2023-2025 | Ingrezza |
| Grifols USA, LLC | $251.63 | 2022-2024 | Prolastin-C Liquid |
| Astrazeneca Pharmaceuticals LP | $245.84 | 2024 | Breztri, Farxiga |
| Teva Pharmaceuticals USA, INC. | $231.09 | 2024-2025 | Austedo Xr |
| Abiomed | $228.52 | 2025 | |
| Paratek Pharmaceuticals, INC. | $226.49 | 2022-2023 | Nuzyra |
| Biogen, INC. | $194.44 | 2022-2023 | |
| Medtronic, INC. | $146.44 | 2025 | Symplicity G3 |
| Shield Therapeutics INC | $125.00 | 2023 | Accrufer |
| Genzyme Corporation | $122.32 | 2022 | |
| Genentech USA, INC. | $113.71 | 2021 | |
| Astellas Pharma US INC | $111.57 | 2024 | Veozah |
| Novo Nordisk INC | $110.96 | 2024 | |
| Novartis Pharmaceuticals Corporation | $106.37 | 2023 |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Horizon Therapeutics Plc | $101.20 | 2022 | |
| Medicure Pharma INC. | $100.17 | 2024 | Zypitamag |
| Abbvie INC. | $88.53 | 2022 | |
| Currax Pharmaceuticals LLC | $82.25 | 2023 | Contrave |
| Otsuka Pharmaceutical Development & Commercialization, INC. | $77.10 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Clelia Lima listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.